This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Teradyne (NASDAQ:TER),
Analysts downgraded five companies: Teradyne (TER) to Neutral with a $420 target, Ternium (TX) to Hold with a $55 target, Health Catalyst (HCAT) to Hold with a $1.8 target, DoubleVerify (DV) to Neutral with a $13.6 target, and Limbach (LMB) to Underweight with a $50 target. Stocks closed at $383.15, $54.21, $1.63, $13.31, and $42.75 respectively.
How this was made
The 30-second read
Why it matters
Downgrades may prompt short positions or profit‑taking.
Market read
Analyst downgrades across multiple stocks may signal broader sector caution.
What to watch
Potential upcoming earnings or product news not yet disclosed.
Background
Analyst rating changes are compiled after recent earnings seasons.
Ticker impact
Baird downgraded Teradyne from Outperform to Neutral, maintaining $420 target.
Modest price decline expected.
Downgrade signals weaker future performance.
HSBC downgraded Ternium SA from Buy to Hold and raised target to $55.
Limited price movement.
Hold rating suggests no strong catalyst.
Canaccord downgraded Health Catalyst from Buy to Hold, cutting target to $1.8.
Potential modest decline.
Target cut reflects weaker expectations.
JP Morgan downgraded DoubleVerify from Overweight to Neutral with $13.6 target.
Sideways to slight down.
No aggressive downgrade, limited impact.
JP Morgan downgraded Limbach Holdings from Neutral to Underweight, target $50.
Possible price drop.
Target cut and lower rating increase bearish view.
Market effects
Broadly affects industrial automation and data‑analytics sectors.
U.S. equities may see slight pressure in related stocks.
Limited to investors tracking analyst rating trends.
Counterpoint
Some investors may view the downgrades as over‑reaction.
Key entities
- Research FirmBaird
Provided downgrade for Teradyne.
- Research FirmHSBC
Downgraded Ternium.
- Research FirmCanaccord Genuity
Downgraded Health Catalyst.
- Research FirmJP Morgan
Downgraded DoubleVerify and Limbach.
